Susquehanna International Group
ABVX

Susquehanna International Group’s Abivax ABVX Stock Holding History

Susquehanna International Group’s Portfolio ABVX Stock Details ABVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$58.6M Buy
525,900
+116,900
+29% +$13.8M 0.01% 1173
2025
Q4 		$55.2M Buy
409,000
+363,800
+805% +$39.7M 0.01% 1279
2025
Q3 		$3.84M Buy
+45,200
New +$2.77M ﹤0.01% 4543

Other funds holding ABVX

TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
DGM
Darwin Global Management St. Helier, Jersey $3.77B AUM 307.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
HI
Helikon Investments London, United Kingdom $2.65B AUM 79.03% 1-Year Est. Return

Susquehanna International Group's ABVX Position: Q1 2026 in Review

Susquehanna International Group reduced its Abivax (ABVX) stake by 49% in Q1 2026, selling an estimated $44.2M and leaving 381,282 shares worth $42.5M. The position accounts for ﹤0.01% of the portfolio, ranked #1417.

Susquehanna International Group first reported a position in ABVX in Q3 2025 and has held it in 3 quarters since. The position peaked at $102M in Q4 2025. 254 funds tracked by Wall St. Rank hold ABVX as of Q1 2026.

  • Susquehanna International Group held 381,282 shares of Abivax worth $42.5M as of Q1 2026.
  • Susquehanna International Group sold 373,554 Abivax shares in Q1 2026, an estimated $44.2M.
  • Abivax made up ﹤0.01% of Susquehanna International Group's portfolio in Q1 2026, its #1417 holding.
  • Susquehanna International Group first reported a position in Abivax in Q3 2025 and has held it in 3 quarters since.
  • Susquehanna International Group's Abivax position peaked at $102M in Q4 2025.
  • 254 funds tracked by Wall St. Rank held Abivax as of Q1 2026.

Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.